"uuid:ID","description","name","id","label","instanceType","rationale"
"ae739889-8da9-48ff-9c78-502e6a763ea5","The main design for the study","Study Design 1","StudyDesign_1","","StudyDesign","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
